| 2933.29.05 | 00 | 1-[1-((4-Chloro-2-(trifluoromethyl)phenyl)- imino)-2-propoxyethyl]-1H-imidazole (Triflumizole); and Ethylene thiourea | kg | Free | | 15.4￠/kg + 52% |
| 2933.29.35 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P,SG) | 15.4￠/kg + 52% |
| 2933.39.61 | | Products described in additional U.S. note 3 to section VI | | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P) 2.9% (SG) | 15.4￠/kg + 52% |
| 2933.49.60 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,L,MA,MX, P) 2.9% (SG) | 15.4￠/kg + 52% |
| 2933.59.22 | 00 | Nicarbazin; and Trimethoprim | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P,SG) | 15.4￠/kg + 46% |
| 2933.59.70 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P) 2.9% (SG) | 15.4￠/kg + 52% |
| 2933.79.08 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P) 2.9% (SG) | 15.4￠/kg + 52% |
| 2933.79.40 | 00 | 12-Aminododecanoic acid lactam | kg | Free | | 30.5% |
| 2933.99.79 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,L,MA,MX, P) 2.9% (SG) | 15.4￠/kg + 52% |
| 2934.10.10 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P) 2.9% (SG) | 15.4￠/kg + 52% |
| 2934.20.40 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,L,MA,MX, P) 2.9% (SG) | 15.4￠/kg + 52% |
| 2934.30.43 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P) 2.9% (SG) | 15.4￠/kg + 52% |
| 2934.99.03 | 00 | 2-Acetylbenzo(b)thiophene; 3-Methylene-7-(2-phenoxyacetamido)- cephan-4-carboxylic acid, p-nitrobenzyl ester, 1-oxide; and Naphth[1,2-d]-[1,2,3]-oxadiazole-5-sulfonic acid and its sodium salt | kg | Free | | 15.4￠/kg + 52% |
| 2934.99.39 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,L,MA,MX, P) 2.9% (SG) | 15.4￠/kg + 52% |
| 2935.00.32 | 00 | Acetylsulfisoxazole; Sulfacetamide, sodium; and Sulfamethazine, sodium | kg | 6.5% | Free (A,AU,BH,CA, CL,E,IL,J,JO, K,MA,MX, P,SG) | 15.4￠/kg + 96% |
| 2935.00.33 | 00 | Sulfathiazole and Sulfathiazole, sodium | kg | Free | | 15.4￠/kg + 133% |
| 2935.00.75 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,L,MA,MX, P) 2.9% (SG) | 15.4￠/kg + 57.5% |
| 2937.40.10 | 00 | l-Thyroxine (Levothyroxine), sodium | kg | Free | | 15.4￠/kg + 49% |
| 2941.10.30 | 00 | Carfecillin, sodium; Cloxacillin, sodium; Dicloxacillin, sodium; Flucloxacillin (Floxacillin); and Oxacillin, sodium | kg | Free | | 15.4￠/kg + 45% |
| 2942.00.03 | 00 | [2,2'-Thiobis(4-(1,1,3,3-tetramethyl-n-butyl)- phenolato)(2,1)]-O,O',S-(1-butanamine), nickel II | kg | Free | | 15.4￠/kg + 46.5% |
| 2942.00.10 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P) 2.9% (SG) | 15.4￠/kg + 46.5% |
| 3002.10.01 | 10 | Human blood plasma | kg | | | |
| 3002.10.01 | 30 | Human immune blood sera | kg | | | |
| 3004.40.00 | 60 | Medicaments primarily affecting the eyes, ears or respiratory system | kg | | | |
| 3004.90.10 | 00 | Containing antigens or hyaluronic acid or its sodium salt | kg | Free | | Free |
